Patents by Inventor Jean-Luc Davignon

Jean-Luc Davignon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS
    Publication number: 20230383350
    Abstract: Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi.
    Type: Application
    Filed: October 19, 2021
    Publication date: November 30, 2023
    Inventors: Jean-luc DAVIGNON, Yannick DEGBOE, Katy DIALLO, Arnaud CONSTANTIN, Benjamin RAUWEL, Jean-Frederic BOYER, Michel BARON
  • Phosphorylated dendrimers as antiinflammatory drugs
    Patent number: 10106565
    Abstract: Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: October 23, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER (TOULOUSE III)
    Inventors: Mary Poupot, Remy Poupot, Jean-Jacques Fournie, Damien Portevin, Severine Fruchon, Jean-Luc Davignon, Cedric-Olivier Turrin, Anne-Marie Caminade, Jean-Pierre Majoral, Olivier Rolland
  • PHOSPHORYLATED DENDRIMERS AS ANTIINFLAMMATORY DRUGS
    Publication number: 20130336997
    Abstract: Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.
    Type: Application
    Filed: July 1, 2013
    Publication date: December 19, 2013
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Mary POUPOT, Remy POUPOT, Jean-Jacques FOURNIE, Damien PORTEVIN, Severine FRUCHON, Jean-Luc DAVIGNON, Cedric-Olivier DAVIGNON, Anne-Marie CAMINADE, Jean-Pierre MAJORAL, Oliver ROLLAND
  • PHOSPHORYLATED DENDRIMERS AS ANTIINFLAMMATORY DRUGS
    Publication number: 20100173871
    Abstract: A method for treating inflammatory diseases through an anti-inflammatory type activation of monocytes, the method includes the administration to a patient in need thereof of an effective quantity of at least one dendrimer with mono- or biphosphonic terminations.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 8, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Mary Poupot, Remy Poupot, Jean-Jacques Fournie, Damien Portevin, Severine Fruchon, Jean-Luc Davignon, Cedric-Olivier Davignon, Anne-Marie Caminade, Jean-Pierre Majoral, Oliver Rolland
  • Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine
    Patent number: 6605467
    Abstract: The invention concerns a fusion protein characterised in that it comprises at least part of the pp65 protein of the cytomegalovirus (or CMV), or a protein having at least 80% homology with the pp65 protein, in combination with at least a second peptide fragment derived from CMV. The invention also concerns a nucleotide sequence coding for such a protein, or a pharmaceutical composition containing them. It further concerns its use as medicine and a method for preparing the protein.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: August 12, 2003
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Prieur, Jacqueline Lule, Jean-Luc Davignon, Christian Davrinche
  • FUSION PROTEIN COMPRISING THE WHOLE OR PART OF THE PP65 PROTEIN OF HUMAN CMV, USEABLE IN PARTICULAR FOR PREPARING A VACCINE
    Publication number: 20020156251
    Abstract: The invention concerns a fusion protein characterised in that it comprises at least part of the pp65 protein of the cytomegalovirus (or CMV), or a protein having at least 80% homology with the pp65 protein, in combination with at least a second peptide fragment derived from CMV. The invention also concerns a nucleotide sequence coding for such a protein, or a pharmaceutical composition containing them. It further concerns its use as medicine and a method for preparing the protein.
    Type: Application
    Filed: July 6, 1999
    Publication date: October 24, 2002
    Inventors: ERIC PRIEUR, JACQUELINE LULE, JEAN-LUC DAVIGNON
  • Method for increasing immunogenicity, product obtained and pharmaceutical compositions
    Patent number: 6342226
    Abstract: The present invention relates to a method for increasing the immunogenicity of an antigen, characterized in that the antigen is combined via stable interactions with a particulate vector, said vector containing: a non-liquid hydrophilic core, and, optionally; an outer layer of compounds chosen from the group comprising phospholipids and fatty acids. The present invention also relates to a product thereby obtained and to a pharmaceutical composition containing such product.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: January 29, 2002
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Christian Davrinche, Jean-Luc Davignon, Eric Prieur